Rising to New Heights: Mark C. McKenna, Visionary in Healthcare, Takes Helm as Chairman of Apogee Therapeutics Board

“From Coast to Coast, a Visionary Voyage: Mark C. McKenna Anchors Apogee Therapeutics, Steering the Ship of Innovation”

SAN FRANCISCO and WALTHAM, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) — Brace yourselves for a seismic shift in the world of biotechnology as Apogee Therapeutics, Inc. (Nasdaq: APGE), a rising star on the clinical-stage horizon, welcomes a new captain on its deck. In a tale that spans from the iconic streets of San Francisco to the vibrant shores of Waltham, Mark C. McKenna emerges as the Chairman of the board of directors—a strategic choice that ripples with promise and potential.

Picture a canvas painted with the hues of innovation—a canvas that bears witness to a company forging a path through atopic dermatitis, chronic obstructive pulmonary disease, and the intricate realm of inflammatory and immunology (I&I) indications. Today, that canvas evolves as Mark C. McKenna takes the helm, steering the ship towards horizons unseen.

“We’ve just welcomed a visionary aboard,” declares Michael Henderson, M.D., the Chief Executive Officer of Apogee, his words infused with excitement. “Mark is no stranger to leading companies to triumph, and his expertise in corporate strategy, development, and commercialization is a treasure we’re thrilled to have. With Mark on board, we’re not just innovating; we’re revolutionizing, bringing differentiated biologics closer to the patients who need them.”

Mr. McKenna’s story resonates with transformation—a tale that reached its zenith at Prometheus Biosciences, Inc., where he wore the hats of President, Chief Executive Officer, and Chairman of the board of directors. His leadership ushered Prometheus into the embrace of Merck & Co., Inc., in a monumental acquisition worth $10.8 billion—a feat that etches his name in biopharma history. Prior to this, he orchestrated a renaissance at Salix Pharmaceuticals, a subsidiary of Bausch Health, doubling revenues to exceed $2 billion while nurturing a legacy of strategic acquisitions.

And as if that weren’t enough, Mr. McKenna’s journey winds through the halls of Bausch + Lomb, leaving footprints of success as he spearheaded the U.S. Vision Care business. His laurels include being crowned Ernst & Young Entrepreneur of the Year in 2023—a testament to his trailblazing spirit. His journey is a tapestry woven with a B.S. in marketing from Arizona State University and an MBA from Azusa Pacific University, and now, his voyage finds its destination at Apogee.

“I step into this role with a sense of honor and excitement,” says Mr. McKenna, his voice brimming with enthusiasm. “Apogee’s potential is boundless, and the canvas of innovation before us holds the promise to reshape lives. Together, with the support of a dynamic team and exceptional directors, we’re on a mission to revolutionize the world of immunology and make a lasting impact on patients.”

Peter Harwin, Managing Member at Fairmount Funds Management and a member of Apogee’s board of directors, echoes the sentiment. “Welcome, Mark—the new Chairman who’ll steer us to even greater heights,” he exclaims. “His journey as a visionary leader, value creator, and strategic guide is a beacon that promises a brighter future for Apogee and the patients we aim to serve.”

From the dynamic landscapes of the biotech world, a chapter of promise unfolds—a chapter where Mark C. McKenna’s wisdom and leadership navigate Apogee Therapeutics towards a new era of innovation, where the canvas of biologics paints a brighter tomorrow for all.

About Apogee Therapeutics

Apogee Therapeutics, Inc. (Nasdaq: APGE) stands at the forefront of innovation in biotechnology, driven by an unwavering mission: to transform the lives of those grappling with atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and other pressing inflammatory and immunology challenges. With a resolute focus on unmet needs, Apogee is pioneering a new era of biologics that transcend the boundaries of conventional treatments.

Guided by ingenuity, Apogee’s antibody programs transcend the norm, targeting well-established mechanisms of action while harnessing cutting-edge antibody engineering to enhance half-life and other vital properties. In the spotlight are the stellar champions of Apogee’s lineup: APG777 and APG808. These remarkable pioneers are poised to rewrite the story of AD and COPD treatment, respectively, setting the stage for a brighter and healthier future.

Apogee’s vision is far-reaching, fueled by an expansive pipeline and a wealth of expertise. In a world where the current standard of care leaves gaps, the company is steadfast in its conviction that it can pave the way for invaluable breakthroughs, delivering tangible, life-changing benefits to those who have long been underserved.

Leave a Comment